You are using an outdated browser. Please upgrade your browser to improve your experience and security.


Dedicated JazzCares specialists are available to assist you or your loved one who has started treatment, in either the inpatient or outpatient setting, with reimbursement for VYXEOS. Call the patient support hotline at 1-855-5VYXEOS (1-855-589-9367)1-855-5VYXEOS (1-855-589-9367) Monday through Friday between 9 AM and 8 PM ET to speak with a specialist.

Ask our JazzCares specialists about…


Understanding your insurance coverage

A specialist can:
  • Investigate your benefits and verify your coverage
  • Help with prior authorization and appeals
  • Answering coding and other reimbursement questions
  • Refer you to financial assistance options

Help paying for your medication*

  • If you have commercial insurance, you may qualify for assistance with out-of-pocket costs for VYXEOS
Hand and Heart

Free-drug program

  • If you are uninsured or do not have coverage for VYXEOS, you may be able to receive VYXEOS for free, if you meet certain eligibility criteria

*Insurance coverage and plans may vary. The JazzCares Program at Jazz Pharmaceuticals provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified healthcare professional.


VYXEOS is a prescription intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders, have a specific genetic mutation, or have certain abnormal blood cells (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.